Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AGIO
SellHot AirAgios Pharmaceuticals, Inc. · Healthcare · United States · $2.0B · Avg Vol: $35M/d
COMPANY DESCRIPTION
Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for genetically defined diseases, particularly in oncology and rare diseases. The company leverages deep expertise in cellular metabolism and a targeted drug discovery approach to address underlying disease mechanisms. Agios has successfully commercialized therapies for rare metabolic disorders and continues to build a pipeline of novel small molecule therapeutics.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.2M | 26.8M | 36.5M | 54.0M | 56.0% | 98.3M | 182.5M | 351.5M | 155.1% |
| EPS | -4.23 | -6.33 | 11.86 | -7.12 | — | -7.01 | -5.63 | -3.69 | — |
| Shares | 55.0M | 55.9M | 57.2M | 58.4M | +6.2% | 59.7M | — | — | — |
| Debt | 85.7M | 72.0M | 57.0M | 40.2M | -22.3% | 31.2M | — | — | — |
| Equity | 1.1B | 811.0M | 1.5B | 1.2B | 2.7% | — | — | — | — |
| Op CF | -309.5M | -296.1M | -389.8M | -373.0M | — | -360.6M | — | — | — |
| Inv CF | 243.3M | 239.6M | 363.4M | 377.2M | — | — | — | — | — |
| Fin CF | 2.4M | 5.4M | 14.4M | 8.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AGIO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AGIO | Agios Pharmaceuticals, Inc.(you) | $2.0B | 32 | Sell |
| ZYME | Zymeworks Inc. | $2.0B | 28 | Sell |
| NUVB | Nuvation Bio Inc. | $2.3B | 31 | Sell |
| VIR | Vir Biotechnology, Inc. | $1.8B | 29 | Sell |
| LBRX | LB Pharmaceuticals Inc | $1.5B | 32 | Sell |
| ANAB | AnaptysBio, Inc. | $1.7B | 34 | Sell |
| BCAX | Bicara Therapeutics Inc. | $1.6B | 30 | Sell |
| ANRO | Alto Neuroscience, Inc. | $1.4B | 32 | Sell |
| XNCR | Xencor, Inc. | $1.9B | 25 | Sell |
| FBRX | Forte Biosciences, Inc. | $1.6B | 28 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.1%